Molecular Pharmacology to start tests on anti-inflammatory drug for tennis elbow

By Ted A. Knutson

Washington, Dec. 16 - Molecular Pharmacology (USA) Ltd. announced Friday that approval had been received from the Medical Ethics Committee of the Curtin University of Technology in Australia for the start of a human clinical trial of MPL-TLB100, the first drug candidate to emerge from the company's newly acquired analgesic and anti-inflammatory product compound.

MPL-TLB100 will be tested for the treatment of lateral epicondylitis, also known as "tennis elbow," a common and painful over-use injury in which the muscles and tendons on the outside of the elbow become inflamed and tender.

MPL-TLB100 is the first of several products based on the proprietary MPL-TL compound (tripeptofen) that will be entered into clinical testing. Additional trial sites and indications are being planned in Australia, Singapore and the United States.

"The move to clinical trials provides us with an opportunity to confirm that the unique analgesic and anti-inflammatory properties of MPL-TLB100. We believe are working with a new molecular entity and mode of action and its very exciting to see so much work coming to fruition," said Jeff Edwards, Molecular Pharmacology technical director, in a press release.

Molecular Pharmacology holds the worldwide exclusive license to manufacture, market and distribute topical anti-inflammatory and analgesic products based on the proprietary MPL-TL compound. Molecular Pharmacology will coordinate with research partners in Singapore and Australia the development of MPL-TLB100 and other compounds based on MPL-TL.

Los Angeles-based Molecular Pharmacology is a public biotechnology company dedicated to the discovery and development of analgesic and anti-inflammatory products based on the proprietary MPL-TL compound.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.